BSE Live
Apr 20, 16:01Prev. Close
147.90
Open Price
150.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 20, 15:58Prev. Close
148.01
Open Price
148.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
144.50 (1153)
| Profit & Loss account of Sun Pharma Advanced Research Company (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 71.77 | 75.55 | 238.78 | 137.25 | 252.96 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 71.77 | 75.55 | 238.78 | 137.25 | 252.96 | |
| Total Operating Revenues | 71.77 | 75.55 | 238.78 | 137.25 | 252.96 | |
| Other Income | 1.79 | 29.47 | 10.88 | 6.84 | 5.41 | |
| Total Revenue | 73.56 | 105.01 | 249.66 | 144.09 | 258.37 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 23.12 | 28.13 | 22.11 | 18.27 | 18.18 | |
| Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating And Direct Expenses | 222.59 | 280.24 | 281.41 | 179.28 | 247.40 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Employee Benefit Expenses | 108.96 | 118.53 | 107.00 | 96.78 | 91.59 | |
| Finance Costs | 8.91 | 1.66 | 7.63 | 13.33 | 10.65 | |
| Depreciation And Amortisation Expenses | 10.83 | 12.13 | 11.77 | 10.16 | 10.92 | |
| Other Expenses | 44.37 | 52.44 | 42.31 | 29.67 | 30.77 | |
| Total Expenses | 418.78 | 493.12 | 472.24 | 347.49 | 409.51 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | -345.22 | -388.11 | -222.58 | -203.40 | -151.14 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | -345.22 | -388.11 | -222.58 | -203.40 | -151.14 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | -345.22 | -388.11 | -222.58 | -203.40 | -151.14 | |
| Profit/Loss From Continuing Operations | -345.22 | -388.11 | -222.58 | -203.40 | -151.14 | |
| Profit/Loss For The Period | -345.22 | -388.11 | -222.58 | -203.40 | -151.14 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | -10.64 | -11.96 | -7.82 | -7.73 | -5.77 | |
| Diluted EPS (Rs.) | -10.64 | -11.96 | -7.82 | 7.73 | -5.77 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
10.02.2026
Sun Pharma Adv Standalone December 2025 Net Sales at Rs 8.45 crore, down 43.33% Y-o-Y
10.02.2026
Sun Pharma Adv Consolidated December 2025 Net Sales at Rs 8.45 crore, down 43.33% Y-o-Y
16.01.2026
17.11.2025
Sun Pharma Adv Consolidated September 2025 Net Sales at Rs 7.86 crore, down 38.88% Y-o-Y
10.02.2026
Sun Pharma Adv Standalone December 2025 Net Sales at Rs 8.45 crore, down 43.33% Y-o-Y
10.02.2026
Sun Pharma Adv Consolidated December 2025 Net Sales at Rs 8.45 crore, down 43.33% Y-o-Y
17.11.2025
Sun Pharma Adv Consolidated September 2025 Net Sales at Rs 7.86 crore, down 38.88% Y-o-Y
12.11.2025
Sun Pharma Adv Standalone September 2025 Net Sales at Rs 7.86 crore, down 38.88% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth